Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles

Daniel Dahis, Dana Meron Azagury, Fadi Obeid, Michelle Z. Dion, Alexander M. Cryer, Mariana Alonso Riquelme, Pere Dosta, Ariel William Abraham, Moshe Gavish, Natalie Artzi, Yosi Shamay, Haim Azhari

Producció científica: Article en revista indexadaArticleAvaluat per experts


Glioblastoma (GBM) is a universally lethal form of brain cancer. The success of novel treatments is hindered by the blood–brain barrier (BBB), which prevents most drugs from penetrating GBM tumors. Sorafenib (SFB), a proapoptotic multikinase inhibitor, has been investigated for the treatment of GBM; however, survival benefit among patients has not improved. Recently, an indocyanine-stabilized nanoparticulate form of SFB (SFB NPs) with improved tumor accumulation was developed in comparison to SFB alone. Herein, the benefit of SFB NPs and focused ultrasound (FUS)-mediated BBB disruption is assessed to enable noninvasive, safe, and reversible BBB permeation for enhanced SFB NPs brain accumulation. Treatment of SFB NPs and FUS yields lower IC50 values (2.7 and 29 μm in 2D and 3D U87 cell models vs 7.5 and 37.1 μm for SFB NPs alone). SFB NPs and FUS with microbubbles improve SFB NPs uptake by U87 cells compared to SFB NPs alone (46% increase; p = 0.0123). In vivo, FUS enhances SFB NPs brain accumulation by 2.5-fold compared to the contralateral hemisphere, and 3.6-fold compared to unsonicated brains. In conclusion, SFB NPs are a promising agent for GBM treatment and its therapeutic capacity can be potentially enhanced when combined with FUS-mediated BBB disruption.

Idioma originalAnglès
Número d’article2200142
RevistaAdvanced NanoBiomed Research
Estat de la publicacióPublicada - de febr. 2023
Publicat externament


Navegar pels temes de recerca de 'Focused Ultrasound Enhances Brain Delivery of Sorafenib Nanoparticles'. Junts formen un fingerprint únic.

Com citar-ho